newsfilter
← Latest News
GlobeNewswire·

Shattuck Labs Announces Phase 1 Results for SL-325

Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1 mg/kg and higherWell